Neuphoria Therapeutics (NEUP) Other Gross PP&E Adjustments (2021 - 2025)
Neuphoria Therapeutics (NEUP) reported Other Gross PP&E Adjustments of -$75219.0 for Q3 2025, up 61.9% year-over-year from -$46459.0 in Q3 2024, and up 26.7% on a QoQ basis from -$102612.0 in Q2 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Other Gross PP&E Adjustments data on file, last reported at -$75219.0 in Q3 2025.
- Quarterly Other Gross PP&E Adjustments rose 61.9% year-over-year to -$75219.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$75219.0 (up 61.9% YoY) and the FY2025 annual result came in at -$102612.0, up 75.0% from the prior year.
- Other Gross PP&E Adjustments grew to -$75219.0 in Q3 2025 per NEUP's latest filing, from -$102612.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$75219.0 in Q3 2025 and bottomed at -$658003.6 in Q2 2021.
- The 4-year median for Other Gross PP&E Adjustments is -$197447.0 (2024), against an average of -$323997.7.
- The widest annual swing landed in 2024, when Other Gross PP&E Adjustments jumped 36.87%; it then soared 75.0% in 2025.
- Tracing NEUP's Other Gross PP&E Adjustments over 4 years: stood at -$546469.5 in 2021, then slipped by 18.96% to -$650080.0 in 2023, then jumped by 76.85% to -$150519.0 in 2024, then jumped by 50.03% to -$75219.0 in 2025.
- Per Business Quant, the three latest NEUP Other Gross PP&E Adjustments figures stand at -$75219.0 (Q3 2025), -$102612.0 (Q2 2025), and -$125213.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -75,219.00 |
| Sep 30, 2025 | -75,219.00 |
| Jun 30, 2025 | -102,612.00 |
| Jun 30, 2025 | -102,612.00 |
| Mar 31, 2025 | -125,213.00 |
| Mar 31, 2025 | -125,213.00 |
| Dec 31, 2024 | -150,519.00 |
| Dec 31, 2024 | -150,519.00 |
| Sep 30, 2024 | -197,447.00 |
| Sep 30, 2024 | -197,447.00 |
| Jun 30, 2024 | -410,416.00 |
| Jun 30, 2024 | -410,416.00 |
| Jun 30, 2023 | -650,080.00 |
| Jun 30, 2023 | -650,080.00 |
| Dec 31, 2021 | -546,469.53 |
| Dec 31, 2021 | -546,469.53 |
| Jun 30, 2021 | -658,003.65 |
| Jun 30, 2021 | -658,003.65 |